Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Manual for Electric Vehicles that will be hot merchants in 2023 - 2Vote In favor of Your #1 Method for diminishing Pressure
- 3IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- 46 Methods for further developing Rest Quality
- 5How a seabird native to Hawaii has adapted to life in Honolulu's concrete jungle
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- The most effective method to Pick the Right Teeth Substitution Choice for You
- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- German inflation soars to 2.7% in March as Iran war drives up prices
- Clovis Unified students spend spring break traveling through China
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Ocean side Objections: Staggering Waterfront Breaks
